Objective: Dopamine is very commonly used in the critical care setting and impacts glucose homeostasis. In some studies, it is noted to increase insulin resistance or decrease insulin secretion. The role of insulin secretion in response to dopamine is incompletely understood.
Methods: Eight individuals underwent a hyperglycemic clamp with a dopamine infusion, and eight controls underwent hyperglycemic clamp alone. Insulin, C-peptide, glucagon, cortisol, and norepinephrine (NE) concentrations were measured at various time points. An index of insulin sensitivity (M/I) was calculated. Statistical comparison between the control and treatment arm was done using repeated measures ANOVA. The data is expressed as mean ± standard deviation. Paired t-test was used to compare pre- and post-dopamine infusion time points in the study individuals only. Data was considered to be statistically significant at P < 0.05.
Results: On assessing the treatment group before and during dopamine infusion, insulin and C-peptide concentrations were higher at the time of the infusion (P = 0.02 and P = 0.003, respectively). The index of insulin sensitivity was not statistically different. There was a significant decrease in insulin (P = 0.002), C-peptide (P = 0.005), and NE (P < 0.0001) concentrations in the treatment group, compared to the controls. Glucagon concentration was higher in the treatment group (P = 0.02).
Conclusion: In this study, dopamine infusion did not adversely impact insulin secretion.
Shankar E, Santhosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 2006;58:157-63.
Rubí B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005;280:36824-32.
García-Tornadú I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010;151:1441-50.
Tomaschitz A, Ritz E, Kienreich K, Pieske B, März W, Boehm BO, et al. Circulating dopamine and C-peptide levels in fasting nondiabetic hypertensive patients: The Graz Endocrine Causes of Hypertension Study. Diabetes Care 2012;35:1771-3.
Contreras F, Foullioux C, Pacheco B, Maroun C, Bolívar H, Lares M, et al. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther 2008;15:397-402.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67:1307-12.
Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L, et al. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun 2015;6:8543.
Bahler L, Verberne HJ, Brakema E, Tepaske R, Booij J, Hoekstra JB, et al. Bromocriptine and insulin sensitivity in lean and obese subjects. Endocr Connect 2016;5:44-52.
Ruttimann Y, Schutz Y, Jéquier E, Lemarchand T, Chioléro R. Thermogenic and metabolic effects of dopamine in healthy men. Crit Care Med 1991;19:1030-6.
Wewer Albrechtsen NJ, Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, et al. Inability of some commercial assays to measure suppression of glucagon secretion. J Diabetes Res 2016;2016:8352957.